Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Aardvark Therapeutics Inc shares valued at $48,440 were purchased by Sun Nelson on Sep 09 ’25. At $8.07 per share, Sun Nelson acquired 6,000 shares. The insider’s holdings grew to 105,484 shares worth approximately $0.84 million following the completion of this transaction.
Also, VICKERS VENT GLB DEEP-TECH FND purchased 20,000 shares, netting a total of over 170,118 in proceeds.
Before that, VICKERS VENT GLB DEEP-TECH FND had added 27,691 shares to its account. In a trade valued at $241,565, the Director bought Aardvark Therapeutics Inc shares for $8.72 each.
As published in their initiating research note from H.C. Wainwright on June 30, 2025, Aardvark Therapeutics Inc [AARD] has been a Buy and the price target has been revised to $40. Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in early March. As of March 10, 2025, Morgan Stanley has initiated its “an Overweight” rating for AARD. Earlier on March 10, 2025, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for AARD stock.
Analyzing AARD Stock Performance
On last trading session, Aardvark Therapeutics Inc [NASDAQ: AARD] rose 1.14% to $8.0. The stock’s lowest price that day was $7.78, but it reached a high of $8.2 in the same session. During the last five days, there has been a drop of approximately -2.20%.
Support And Resistance Levels for Aardvark Therapeutics Inc (AARD)
According to the 24-hour chart, there is a support level at 7.71, which, if violated, would cause prices to drop to 7.42. In the upper region, resistance lies at 8.28. The next price resistance is at 8.56. RSI (Relative Strength Index) is 34.03 on the 14-day chart, showing neutral technical sentiment.
Is Aardvark Therapeutics Inc subject to short interest?
Stocks of Aardvark Therapeutics Inc saw a sharp steep in short interest on 2025-08-15 dropping by 293.0 shares to 0.66 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 0.66 million shares. A decline of -0.04% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 14.32 of the overall float, the days-to-cover ratio (short ratio) decline to 14.32.
Which companies own the most shares of Aardvark Therapeutics Inc (AARD)?
In terms of Aardvark Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 29 in the next 12 months, up nearly 266.62% from the previous closing price of $7.91. Analysts anticipate Aardvark Therapeutics Inc stock to reach 29 by 2025, with the lowest price target being 29. On March 10, 2025, BofA Securities assigned a price target of “a Buy” to the stock and initiated coverage with a $22.
